Fundamentals of ESR: Implementing Appropriate Scoring Systems in Prostate MRI

Overview

Prostate MRI is essential in prostate cancer management, with standardized scoring systems like PI-RADS v2.1 guiding detection and localization of clinically significant cancer. Additional tools such as PI-QUAL, PRECISE, and PI-RR support image quality assessment, active surveillance, and recurrence evaluation, respectively. Proper application of these scoring systems ensures consistent reporting and effective clinical communication.

Background

Prostate MRI plays a central role in the diagnosis and management of prostate cancer. The Prostate Imaging Reporting and Data System (PI-RADS) standardizes the acquisition, interpretation, and reporting of prostate MRI to detect clinically significant cancer in treatment-naïve patients. Other MRI-based scoring systems have been developed to assess image quality, monitor changes during active surveillance, and evaluate local recurrence after treatment. Despite their availability, confusion remains regarding the appropriate use and timing of these scoring tools within clinical workflows.

Data Highlights

The PI-RADS scoring system uses a 5-point scale to estimate the likelihood of clinically significant prostate cancer (csPCa), defined as Gleason score ≥ 3 + 4, tumor volume ≥ 0.5 cc, or extraprostatic extension. The dominant MRI sequences differ by prostate zone: diffusion-weighted imaging (DWI) for the peripheral zone and T2-weighted imaging (T2W) for the transition zone. Dynamic contrast-enhanced (DCE) imaging plays a minor role, mainly upgrading indeterminate lesions. No more than four lesions should be reported per exam, with standardized lesion measurement and diagrammatic representation to facilitate communication and biopsy targeting.

Key Findings

• PI-QUAL is the standardized tool for assessing prostate MRI image quality and should be used before interpretation.
• PI-RADS v2.1 is recommended for prostate MRI interpretation before biopsy in men with clinical suspicion of prostate cancer, focusing on detection and localization of clinically significant lesions.
• PI-RADS scoring is zone-specific, combining T2W, DWI, and DCE sequences, with DWI dominant in the peripheral zone and T2W dominant in the transition zone.
• PRECISE scoring predicts radiological changes during active surveillance, while PI-RR estimates local recurrence risk after whole-gland treatments.
• Non-contrast biparametric MRI (bpMRI) may be considered in biopsy-naïve patients with high-quality imaging and expert interpretation, though the role of DCE remains debated.
• Consistent use of appropriate scoring systems improves report standardization and communication between radiologists and clinicians.

Clinical Implications

Clinicians should ensure prostate MRI is performed with adequate image quality assessed by PI-QUAL before interpretation. PI-RADS v2.1 should be applied for biopsy-naïve patients to guide clinical decision-making and reduce unnecessary biopsies. For patients under active surveillance or post-treatment, PRECISE and PI-RR scoring systems provide valuable prognostic information. Adhering to these guidelines promotes standardized reporting and optimizes patient management.

Conclusion

Appropriate implementation of prostate MRI scoring systems tailored to clinical scenarios enhances diagnostic accuracy and patient care. Standardization through tools like PI-RADS, PI-QUAL, PRECISE, and PI-RR facilitates consistent reporting and effective multidisciplinary communication.

References

1. ESUR Guidelines 2024 -- Fundamentals of ESR: Implementing Appropriate Scoring Systems in Prostate MRI